Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome

References

• Sarwar N, Gao P, Seshasai SR, Emerging Risk Factors Collaboration, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative Meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Buntaine AJ, Shah B, Lorin JD, et al. Revascularization strategies in patients with diabetes mellitus and acute coronary syndrome. Curr Cardiol Rep. 2016;18(8):79.
   PubMed Web of Science ®Google Scholar
• Pandey A, McGuire DK, de Lemos JA, et al. Revascularization trends in patients with diabetes mellitus and multivessel coronary artery disease presenting with Non-ST elevation myocardial infarction: Insights from the national cardiovascular data registry acute coronary treatment and intervention outcomes network Registry-Get with the guidelines (NCDR ACTION Registry-GWTG). Circ: Cardiovascular Quality Outcomes. 2016;9(3):197–205.
   PubMed Web of Science ®Google Scholar
• Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and All-Cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–1395.
   PubMed Web of Science ®Google Scholar
• Sumarjaya I, Nadha IKB, Lestari AAW. High lipoprotein(a) levels as a predictor of major adverse cardiovascular events in Hospitalized-Acute myocardial infarction patients. Vasc Health Risk Manag. 2020;16(:125–132.
   PubMed Web of Science ®Google Scholar
• Mitsuda T, Uemura Y, Ishii H, et al. Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels. 2016;31(12):1923–1929.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Dohi T, Funamizu T, et al. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention. J Cardiol. 2020;76(1):25–29.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9(:617–670.
   PubMedGoogle Scholar
• Gragnano F, Fimiani F, Di Maio M, et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med. 2019;14(4):621–625.
   PubMed Web of Science ®Google Scholar
• Chen Z, Jiang C, Qu H, et al. Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention. AOMS. 2019;15(6):1375–1380.
   Web of Science ®Google Scholar
• Gencer B, Rigamonti F, Nanchen D, et al. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. Eur J Clin Invest. 2019;49(7):e13117.
   PubMed Web of Science ®Google Scholar
• Schmitz G, Orsó E. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl. 2015;10(Suppl 1):21–25.
   PubMedGoogle Scholar
• Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
   PubMed Web of Science ®Google Scholar
• Moldogazieva NT, Mokhosoev IM, Mel'nikova TI, et al. Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and Age-Related diseases. Oxid Med Cell Longev. 2019;2019:3085756.
   PubMed Web of Science ®Google Scholar
• Prasad K, Tiwari S. Therapeutic interventions for advanced Glycation-End products and its Receptor- Mediated cardiovascular disease. Curr Pharm Des. 2017;23(6):937–943.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Szarek M, Bittner VA, ODYSSEY OUTCOMES Committees and Investigators, et al. Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment. Diabetes Care. 2021;44(5):1219–1227.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jin JL, Cao YX, et al. Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):111.
   PubMed Web of Science ®Google Scholar
• Tam DY, Dharma C, Rocha RV, et al. Revascularization strategies for the treatment of multivessel coronary artery disease in patients with diabetes mellitus. Circ Cardiovasc Interv. 2020;13(9):e009082.
   PubMed Web of Science ®Google Scholar
• Saeed A, Sun W, Agarwala A, et al. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study Atherosclerosis. 2019;282:52–56.
   PubMed Web of Science ®Google Scholar
• Cesaro A, Schiavo A, Moscarella E, et al. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med. 2021;22(3):151–161.
   Google Scholar
• Bigazzi F, Minichilli F, Sbrana F, et al. Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(3):158869.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk Circulation. 2019;139(12):1483–1492.
   PubMed Web of Science ®Google Scholar
• Bittner VA, Szarek M, Aylward PE, ODYSSEY OUTCOMES Committees and Investigators, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133–144.
   PubMed Web of Science ®Google Scholar